Tag Archives: MiniMed

October CHMP Agenda Highlights; Pfizer Initiates Q3M Berobenatide Study; Novo Licenses New Drug Discovery Platform; Fractyl Shares 6-Month Revita Procedure Results; FDA Reaffirms Reta’s Classificaiton as a Drug; MiniMed Appoints Board; Sequel twiist AID Insulin-Treated T2DM FDA Clearance

A series of cardiometabolic-related news items has been observed from EMA, Pfizer, Novo/Ablexis, Fractyl Health, FDA/Lilly, MiniMed, and Sequel Med Tech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novartis Terminates Ph3 Pelacarsen Studies; AZ Partners with insitro; Dexcom Publishes CONNECT RCT Results; Pfizer China-Based QM Berobenatide Obesity Study; Modular Medical Digital Learning Tool; Medtronic Finalizes MiniMed Separation; Atrogi Oral GRK2-Biased ß2-Adrenergic Modulator Data

A series of cardiometabolic-related news items has been observed from Novartis, AstraZeneca, Dexcom, Pfizer, Modular Medical, MiniMed, and Atrogi AB. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

MiniMed Initiates 16-day CGM Study; FDA Accepts Bayer’s Finerenone Non-T2DM CKD sNDA; Ribo Life Science Submits Ph1 Application for INHBE siRNA Obesity Study in EU

Three cardiometabolic-related news items have been observed: MiniMed has registered a new study of its next-gen extended-wear CGM, called Unity (view CT.gov record); FDA accepted Bayer’s sNDA for finerenone in non-T2DM CKD (view press release); and Suzhou Ribo Life Science submitted a Ph1 CTA in the EU for its INHBE siRNA in obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Following ADA 2026 (June 5-8; New Orleans, LA), FENIX conducted a winners/not winners analysis, identifying the companies that came out on top, remained static, or trended in the wrong direction. As a glimpse into the analysis, Lilly (unsurprisingly) clearly came out on top, with the retatrutide pivotal data session filling the room beyond capacity. The ADA organization seemingly had the most negative outcome following the controversy around Steven Kahn’s removal from the event.

This content is for Read Less members only.
Already a member? Log in here